ADVERTISEMENT

User Fees

US FDA Reorganization Set Stage To Improve Food Programs, But Slim Budget Grabs Spotlight

“It's kind of a free for all,” says longtime FDA funding advocate Steven Grossman. FDA knew funding it requested “was totally inadequate to the needs. So, Food Chemical Safety is stuck there with about six or eight other purposes the money could have been used for.

US Monograph Facility Fees Due In Six Weeks While DOGE Subjects FDA To Rapid Changes

FDA’s OMUFA facility fees for FY2025, due on 2 June, increase nearly $2,400 to $37,556 for OTC monograph drug manufacturers and $2,200 to $25,037 for contract manufacturers. Overall target OMUFA fee total is just short of $36.47m, up from $32.25m for FY2024.

User Fees: Industry Should Push For Extension Of Current Agreement In Reconciliation Bill, Gottlieb Says

Trump’s former FDA commissioner sees ‘nothing good’ coming from negotiating a new user fee agreement in the ‘current political environment.’

US FDA Meets OTC Monograph Program Overhaul Deadlines But Notes Facility Fees Behind Schedule

FDA Office of Nonprescription Drugs explains in its proposed commitment letter for fiscal years 2026-2030, based in part on suggestions by stakeholders, that it will heighten its attention to collecting those fees.

Looking For STARs: US FDA Expands Split Real Time Review Amid Low Supplement Interest

The STAR pilot established in PDUFA VII for efficacy supplements, which was modeled after the popular Real Time Oncology Review program, has not garnered much interest. The agency now is establishing a separate but similar pilot for a small number of original NDAs and BLAs.

US FDA’s New Voucher Fee Reveals Standard, Priority Review Cost Spike

The number of standard and priority reviews also decreased significantly in FY 2023 compared to the previous year, which caused the fee for redeeming a voucher to rise.

US FDA Forecasts Monograph Program Activities As Overhaul Transitions From Construction Phase

Nonbinding forecast, fourth for the program, includes risks associated with codeine-containing cough medicine as a topic FDA will include in ongoing evaluation of GRASE for pediatric cough cold drug products marketed under monograph for cold, cough, allergy, bronchodilator and anti-asthmatic OTC drugs.

US FDA's Slim October User Fee Calendar Brings Some Controversy

Advisory committee concerns cast clouds over Iterum’s oral antibiotic, Intercept’s Ocaliva, and perioperative immuno-oncology regimens, while CSL and Pfizer aim to take their hematology franchises in new directions.

Inflation Continues To Rear Head At US FDA User Fees

Inflation accounted for a larger portion of user fee revenue target increases for fiscal year 2025, compared to previous years, according to a Pink Sheet analysis.

Model-Informed Drug Development Program Could Handle More Requests, But US FDA Needs Funding

FDA is considering allowing MIDD meeting requests to be submitted more often than the current quarterly schedule, but agency must have a plan to deal with the likely increased demand, official says.